Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BlissBio logo — Bliss Bio is a biopharmaceutical company focused on developm...

BlissBio

Bliss Bio is a biopharmaceutical company focused on development of tumor targeting and immunotherapy drugs.

Founded 2017 Series B Total: $500.00M Biopharma, Biotechnology +1

General Information

Company Name BlissBio
Founded Year 2017
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with BlissBio. To contact BlissBio, visit blissbiopharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About BlissBio

BlissBio is a biopharmaceutical company founded in 2017 with a focus on developing tumor targeting and immunotherapy drugs. The latest milestone for the company was a CNY100.00M Series B investment on 18 January 2023. This significant investment came from notable backers including In Capital, Oriental Fortune Capital, and Sherpa Venture Capital. With a strong emphasis on biopharma, biotechnology, and pharmaceuticals, Bliss Bio is positioning itself as a key player in the development of innovative and impactful treatment solutions within the biopharmaceutical space.

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B CNY100.00M 3
In Capital Oriental Fortune Capital
In Capital, Oriental Fortune Capital +1
18 Jan 2023
Series B CNY400.00M 6
Sherpa Capital Cormorant Asset Management Oriental Fortune Capital
Sherpa Capital, Cormorant Asset Management +4
16 Apr 2021

BlissBio Alternatives & Competitors

View All Alternatives
BlissBio vs
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. Canada

A neuroscience-focused biopharmaceutical company

Post-IPO Equity
333 employees
Biopharma, Biotechnology
BlissBio vs
Laminar Pharma
Laminar Pharma Spain

Biopharmaceutical company performing discovery, rational design and initial clinical development of...

39 employees
Biotechnology, Life Sciences
BlissBio vs
HilleVax
HilleVax United States

HilleVax is a biopharmaceutical company focused on the development and commercialization of novel va...

Post-IPO Equity
76 employees
Biopharma, Biotechnology
View all alternatives

FAQ About BlissBio

Bliss Bio is a biopharmaceutical company focused on development of tumor targeting and immunotherapy drugs.
BlissBio was founded in 2017.
BlissBio operates in Biopharma, Biotechnology and Pharmaceutical.
BlissBio has completed 2 funding rounds, raising a total of $500.00M. The latest funding stage is Series B.
Top alternatives and competitors to BlissBio include Xenon Pharmaceuticals Inc., Laminar Pharma, HilleVax, ASLAN Pharmaceuticals, Inventiva Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BlissBio and Xenon Pharmaceuticals Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BlissBio, https://bouncewatch.com/company/blissbio, updated 19 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes